Compare DEI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEI | PTGX |
|---|---|---|
| Founded | 1971 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 9.5B |
| IPO Year | 2006 | 2016 |
| Metric | DEI | PTGX |
|---|---|---|
| Price | $11.58 | $158.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $12.94 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 1.8M | 470.6K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | ★ $1,003,982,000.00 | N/A |
| Revenue This Year | $1.70 | $874.25 |
| Revenue Next Year | $2.35 | N/A |
| P/E Ratio | ★ N/A | $67.50 |
| Revenue Growth | ★ 1.77 | N/A |
| 52 Week Low | $9.04 | $55.26 |
| 52 Week High | $16.94 | $158.95 |
| Indicator | DEI | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 71.61 |
| Support Level | $11.14 | $94.48 |
| Resistance Level | $11.68 | N/A |
| Average True Range (ATR) | 0.35 | 5.13 |
| MACD | -0.02 | 1.22 |
| Stochastic Oscillator | 39.11 | 93.80 |
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.